Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·
Return to Directory

Tirzepatide

Technical Monograph

Tirzepatide is a deeply engineered, 39-amino acid synthetic peptide that functions as a single-molecule dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Uniquely constructed utilizing the native GIP sequence as its structural backbone, it exhibits highly biased signaling, prioritizing GIP engagement over GLP-1 to maximize metabolic rate modulation while mitigating severe gastrointestinal stall.

Mechanism of Action

The peptide binds potently to dual incretin receptors. GIP receptor activation primarily limits ectopic fat deposition, enhances insulin sensitivity in white adipose tissue, and upregulates lipid buffering capacity. GLP-1 receptor activation significantly delays gastric emptying and centrally governs satiety via arcuate nucleus stimulation. The synergistic dual-action corrects generalized metabolic dysfunction with significantly greater efficacy than mono-agonists.

Pharmacological Detail

Binds exclusively to Class B1 GPCRs. Promotes robust beta-arrestin recruitment at the GIP receptor while deliberately limiting beta-arrestin recruitment at the GLP-1 receptor (biased agonism), preventing rapid receptor down-regulation.

Pharmacodynamics

Suppresses post-prandial glucagon secretion, upregulates highly efficient lipid oxidation pathways, and substantially diminishes centrally mediated caloric demand.

Pharmacokinetics

Exhibits a prolonged half-life of 116.5 hours (approx. 5 days), supporting steady-state systemic concentrations with weekly administration. Peak plasma concentrations are reached in 8-72 hours post-SC injection.

Preclinical Observations & In Vitro Data

Extensively verified in non-human primate and murine metabolic models yielding unparalleled total mass reductions (-20%+) accompanied by sweeping normalization of hepatic lipid content.

Preclinical (Diet-Induced Obese Mice): Total fat mass reduction of 41% alongside complete normalization of fasting glucose levels within 14 days of initiated protocol.
Preclinical (NHP): Significant reduction in measurable caloric intake persisting up to 6 days post-injection. Liver triglyceride content reduced by over 50%.

Observed Timeline of Action

TimeframePharmacological Effect
8-24 hoursInitial suppression of gastric emptying velocity and early satiety signaling.
4-5 weeksAchievement of steady-state circulating peptide concentrations.
24-36 weeksClinical plateau for maximal total-body mass reduction in continuous treatment models.

Abstract Highlights

  • Demonstrates imbalanced affinity: binding human GIP receptors with equal affinity to native GIP, while binding GLP-1 at ~20% the affinity of native GLP-1
  • Achieves superior HbA1c normalization via enhanced beta-cell function and generalized insulin sensitivity over pure GLP-1 agents
  • A structural C20 fatty diacid moiety attached via a hydrophilic linker heavily resists enzymatic degradation and prolongs plasma binding

References

Coskun T, et al. (2018)."Tirzepatide is a novel, dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes."Molecular Metabolism.
Willard FS, et al. (2020)."Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist."JCI Insight.

Chemical Specifications

4813.5 g/mol
C225H348N48O68
Y-Aib-EGTFTSDYSI-Aib-LDKIAQ-(C20-fatty-diacid)-AFVQWLIAGGPSSGAPPPS

Material Handling & Stability

Laboratory StorageLyophilized powder: Stable at -20°C for at least 3 years.
Aqueous StabilityReconstituted: Bacteriostatic preparation stable at 2-8°C for up to 30 days due to the inherently robust C20 acylated structure.

Strict Notice

THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.